Crossmark

Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study—IL AD (Italian Landscape Atopic Dermatitis)

Crossref DOI link: https://doi.org/10.1007/s00403-025-04278-9

Published Online: 2025-05-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Potestio, Luca

Patruno, Cataldo

Narcisi, Alessandra

Costanzo, Antonio

Ibba, Luciano

Gargiulo, Luigi

Malagoli, Piergiorgio

Ortoncelli, Michela

Ribero, Simone

Mastorino, Luca

Leo, Francesco

Ferrucci, Silvia Mariel

Angileri, Luisa

Barei, Francesca

Stingeni, Luca

Hansel, Katharina

Sciarrone, Claudio

Girolomoni, Giampiero

Maurelli, Martina

Foti, Caterina

Tirone, Benedetta

Balato, Anna

Esposito, Maria

Paolino, Giovanni

Mercuri, Santo Raffaele

Pezzolo, Elena

Savoia, Paola

Brescia, Claudio

Napolitano, Maddalena
Funding

Funding for this research was provided by:

Università degli Studi di Napoli Federico II
License Information

Text and Data Mining valid from 2025-05-23

Version of Record valid from 2025-05-23
More Information

Article History

Received: 27 February 2025

Revised: 21 April 2025

Accepted: 6 May 2025

First Online: 23 May 2025

Declarations

:

: The authors declare no competing interests.

: Not required.

Document is current

Any future updates will be listed below